The strong EPS beat and revenue surprise, combined with pipeline catalysts (PRT12396 Phase 1 enrollment, upcoming KAT6A IND) and extended cash runway, are likely to drive near-term upside. Monitor for PRT13722 IND filing by mid-2026 and Phase 1 data readouts for PRT12396 as key catalysts.
Price Chart
Executive Summary
Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensus). The beat was driven by lower R&D spend after pausing SMARCA2 trials, while the pipeline advanced with PRT12396 Phase 1 enrollment initiation and a $90M offering extending cash runway into Q2 2028.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.13 vs consensus -$0.27 (beat by 51.9%)
- Revenue $4.58M from $0 in prior year period (Incyte option agreement revenue)
- Net loss narrowed to $10.4M from $32.1M YoY
- Cash, equivalents, and marketable securities $84.8M at March 31, 2026
- Completed $90M underwritten offering post-quarter, extending cash runway into Q2 2028
- Initiated Phase 1 enrollment for PRT12396 (JAK2V617F inhibitor) in PV and MF
- IND filing for PRT13722 (KAT6A degrader) expected mid-2026, Phase 1 in 2H 2026
- Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026
Financial Impact
EPS beat of 51.9% vs consensus; revenue surprise of $4.58M vs $0 consensus; net loss reduction of 67.6% YoY
Risk Factors
- Clinical-stage biotech with no approved products; pipeline failure risk
- Dependence on Incyte option agreement for JAK2 program revenue
- Dilution from $90M offering (shares outstanding increased significantly post-quarter)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers